Latest Articles
-
Abbott Labs: Board Approves Split As Jan 1 Nears
Abbott Labs ‘ (NYSE:ABT) board has approved the separation of the company into two separate publicly traded companies: one, Abbott, with diversified medical products, and the other, AbbVie, with research-based proprietary pharmaceuticals. A...
-
Lessons from the Liver Meeting: Sagient’s John Tucker Names Companies That Could Reignite the Hepatitis C Industry
Submitted by The Life Sciences Report as part of our contributors program . This interview was conducted by George S. Mack of The Life Sciences Report and can be read in its entirety here . The hepatitis C (HCV) market was white hot in 201...
-
Abbott Labs Updates: Europe Approves Humira For Severe Crohn’s Disease in Children
Abbott Labs ‘ (NYSE:ABT) highest-selling drug, Humira, continues to add additional indications as the European Medicines Agency (EMA) has approved the drug for the treatment of severe active Crohn’s Disease in pediatric patients who f...
-
Abbott Patent Cliff: A Look At The Autoimmune and HIV Antiviral Divisons
In the next few several blockbuster drugs will lose patent exclusivity, which will result in the loss of over $100 billion in revenues across the pharmaceutical industry. After a drug’s patent expires, generic manufacturers can replic...
-
How Abbot Labs Reaches $67 Fair Value
This year through October big pharmaceutical companies have seen a surge in their stock prices. With close to 30-35% return, Abbott Labs (NYSE:ABT) has outperformed the overall healthcare sector. But the stock slumped almost 10% from the highs se...
-
3 Bio-Pharmas Trades Offering Good Upside Potential
Submitted by Scott Matusow as part of our contributors program . With some added confidence shown by investors yesterday, it’s a good time to look at some “risk on” small cap bio-pharma stocks that I feel offer good upside fo...
-
Is There Big Value In Addiction Fighting Pharmas?
Submitted by Morgan Smith as part of our contributors program . In the past, addiction has been ultimately seen as a weakness of will or an inability of the addict at some level to exercise self control. Treatment regimens involved a course of p...
-
Analyst Scott Power Finds the Upside in Biotech Down Under
Submitted by The Life Sciences Report as part of our contributors program . This interview was conducted by George S. Mack of The Life Sciences Report (11/8/12) If you’re looking for fresh international names in biotech and medtech, but...
-
Abbott Labs: A Look At The Company Post Spin-Off
Abbott Labs ‘ (NYSE:ABT) spin-off process seems to be on the right track as the healthcare conglomerate has closed one of the largest dollar denominated bond deals in the last three years, raising close to $15 billion in debt through its un...
-
Pfizer Receives Big Boost As FDA Approves Rheumatoid Arthritis Drug
After witnessing delays in approval, Pfizer ‘s (NYSE:PFE) much anticipated drug Xeljanz (more popularly known as Tofacitinib) has finally managed to receive the U.S. Food and Drug Administration (FDA) approval for rheumatoid arthritis (RA)...
-
Boston Scientific, Abbott Face Threat As NIH Study Could Hurt Stent Sales
A National Institutes of Health (NIH) funded 5-year long study recently concluded that bypass surgery is far more cost-effective over a period of time compared to stents in diabetic patients. This finding may add to the worries of medical devices...
-
5 Dividend Stocks Investors Mostly Dislike
Submitted by Dividend Yield as part of our contributors program . Stocks With Recent Short Activities By Investment Professionals Researched By Dividend Yield – Stock, Capital, Investment . Investment gurus are asset or fund managers with big ...
-
Abbott’s Potential Downside To A Decline In Humira And Weaker Margins
The last couple of months have been impressive for pharmaceutical companies as stock prices have zoomed higher by 20-30%. Abbott Labs (NYSE:ABT) also rose significantly to exceed our $67 price estimate before slumping to $65 as many were disappo...
-
A Summary Of The 20 Safest Dividend Growth Picks
Submitted by Dividend Yield as part of our contributors program . Dividend Achievers With Low Beta Ratios Researched By “ long-term-investments.blogspot.com “. Dividend growth is an investment strategy that works if you have enough...
-
Abbott Labs: Humira Growth Disappoints
Abbott Labs (NYSE:ABT) reported its Q3 results last Wednesday, which were below market expectations. On a constant currency basis, sales grew by 4% y-o-y to about $9.8 billion on less than expected growth in its key drugs including Humira, AndroG...
